Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study

C. Fountzilas, Roswell Park Comprehensive Cancer Center, NY
A.H. Ko, University of California at San Francisco
E.H. Borazanci, HonorHealth Research Institute, AZ
J.T. D'Olimpio, Clinical Research Alliance, NY
J.R. Hecht, University of California at Los Angeles
Shou-Ching Tang, LSU Health Sciences Center - New Orleans
A.F. Shields, Wayne State University, MI
M.A. Salkeni, Virginia Cancer Specialists Research Institute
G.C. Michelson, CG Pharmaceuticals Inc.
L. Liganor, CG Pharmaceuticals Inc.
G. Cho, CG Pharmaceuticals Inc.
S.A. Cho, CG Pharmaceuticals Inc.
E.J. Walker, University of California at San Francisco

Abstract 742

Abstract

2025 ASCO Gastrointestinal Cancers Symposium, January 23 - 25, 2025, San Francisco, CA